Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

Abstract Background Diabetic macular oedema (DMO) may lead to visual loss and blindness. Several pharmacological treatments are available on the National Health Service (NHS) to United Kingdom patients affected by this condition, including intravitreal vascular endothelial growth factor inhibitors (...

Full description

Bibliographic Details
Main Authors: Michal Pochopien, Annette Beiderbeck, Phil McEwan, Richard Zur, Mondher Toumi, Samuel Aballéa
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Health Services Research
Subjects:
Fluocinolone acetonide implant
Diabetic macular oedema
Cost-effectiveness
Treatment cost
Incremental cost-effectiveness ratio
Online Access:http://link.springer.com/article/10.1186/s12913-018-3804-4

Internet

http://link.springer.com/article/10.1186/s12913-018-3804-4

Similar Items